Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary cells suppress oncogene-dependent apoptosis.

D M Duelli1, Y A Lazebnik

  • 1Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA.

Nature Cell Biology
|November 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic locus required for antigenic maturation of Rhizobium etli CE3 lipopolysaccharide.

Journal of bacteriology·2001
Same author

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.

Nature·2001
Same author

Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.

Blood·2000
Same author

Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c.

The Journal of biological chemistry·1999
Same author

Oncogene-dependent apoptosis is mediated by caspase-9.

Proceedings of the National Academy of Sciences of the United States of America·1998
Same author

Oncogene-dependent apoptosis in extracts from drug-resistant cells.

Genes & development·1997
Same journal

Addendum: In situ architecture of the human prohibitin complex.

Nature cell biology·2026
Same journal

Evolutionarily conserved short linear motifs drive actin filament binding.

Nature cell biology·2026
Same journal

CD44 restricts EGFR mobility to polarize cytoskeletal signalling modules driving bleb-based migration.

Nature cell biology·2026
Same journal

Author Correction: Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance.

Nature cell biology·2026
Same journal

An atlas of primate insular cortex reveals a signal-processing strategy in von Economo neurons.

Nature cell biology·2026
Same journal

Primate neurons with special signalling logic.

Nature cell biology·2026
See all related articles

The adenoviral oncogene E1A sensitizes cancer cells to drugs by activating cell death pathways and blocking survival signals. This dual action enhances anti-cancer drug effectiveness by overcoming natural cell defenses.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Virology

Background:

  • Oncogenes driving cell growth can also increase cancer cell susceptibility to apoptosis.
  • Inhibitors of apoptosis normally protect cells from programmed cell death.

Purpose of the Study:

  • To investigate the mechanisms by which the adenoviral oncogene E1A sensitizes cells to anti-cancer drugs.
  • To identify the specific pathways involved in E1A-mediated drug sensitization.

Main Methods:

  • Utilized cell-based assays to study the effects of the adenoviral E1A oncogene.
  • Investigated the interplay between E1A, an anti-cancer drug, and apoptotic pathways.
  • Analyzed the role of apoptosis inhibitors in drug response.

Main Results:

Related Experiment Videos

  • The adenoviral oncogene E1A sensitizes cells to a specific anti-cancer drug.
  • E1A activates at least two distinct pathways contributing to drug sensitization.
  • One pathway links the drug to pro-apoptotic factors, while a second pathway suppresses apoptosis inhibitors.

Conclusions:

  • The adenoviral oncogene E1A employs a multi-pronged strategy to enhance anti-cancer drug efficacy.
  • Suppression of apoptosis inhibitors by E1A is crucial for drug sensitization, complementing the induction of cell death.
  • Understanding these pathways could inform the development of more effective cancer therapies.